Physician profile
Natalie E Cook
NPI 1164914214
$1,854.57
in general payments reported to CMS, 2019-2025
24 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $286 · 2023: $427 · 2024: $508 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.49 | 2022-2025 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $134.25 | 2022-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $130.14 | 2022-2024 | Jardiance, Zepbound |
| Pfizer INC. | $114.37 | 2023-2025 | |
| Dexcom, INC. | $107.68 | 2022-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $82.29 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $68.28 | 2023-2025 | Ozempic, Rybelsus, Saxenda |
| Amgen INC. | $62.82 | 2022-2025 | Prolia, Evenity, Repatha |
| Merck Sharp & Dohme LLC | $61.58 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Alexion Pharmaceuticals, INC. | $51.87 | 2022-2024 | Ultomiris |
| Inspire Medical Systems, INC. | $47.42 | 2024 | Inspire |
| Radius Health, INC. | $44.77 | 2023-2025 | Tymlos |
| Astellas Pharma US INC | $41.92 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $38.83 | 2022-2025 | |
| Glaxosmithkline, LLC. | $35.36 | 2023-2025 | Trelegy Ellipta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.33 | 2022-2024 | Xarelto |
| Sumitomo Pharma America, INC. | $25.63 | 2025 | Gemtesa |
| Boston Scientific Corporation | $24.48 | 2023 | |
| Daiichi Sankyo INC. | $24.27 | 2024 | Injectafer |
| Axsome Therapeutics, INC. | $20.49 | 2025 | Auvelity |
| Medtronic, INC. | $19.49 | 2022 | |
| Seqirus USA INC | $19.38 | 2025 | Fluad, Flucelvax |
| Esperion Therapeutics, INC. | $16.79 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $14.64 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.